

Supplementary Table 1. Treatments of interest in multiple sclerosis

| Product | Position in the treatment strategy |
|------------------------|--|
| Diméthyl fumarate | Moderate efficacy treatment |
| Glatiramere acetate | Moderate efficacy treatment |
| Interferon beta-1-a | Moderate efficacy treatment |
| Interferon beta-1-b | Moderate efficacy treatment |
| Peginterferon beta-1-a | Moderate efficacy treatment |
| Teriflunomide | Moderate efficacy treatment |
| Fingolimod | High efficacy treatment |
| Natalizumab | High efficacy treatment |
| Cladribine | Not applicable ^a |
| Rituximab | Not applicable ^a |
| Alemtuzumab | Not available in the SNDS ^b |
| Mitoxantrone | Not available in the SNDS ^b |

SNDS, Système National des Données de Santé.

^aThese treatments were only used to determine the naïve/non-naïve status of patients.

^bThese treatments cannot be used because they are not identifiable in the SNDS. Indeed they are dispensed only at hospital and included in the diagnosis-related group.